Kolltan Pharmaceuticals Inc. Appoints Ronald A. Peck, M.D., Chief Medical Officer And SVP, Clinical Development

NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, Inc. ("Kolltan" or the "Company"), a privately held clinical-stage company focused on the discovery and development of novel, best-in-class antibody-based drugs targeting receptor tyrosine kinases for the treatment of cancer and other diseases, today announced the appointment of Ronald A. Peck, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development.